Literature DB >> 18362500

Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy.

J H Li1, N Zhang, J A Wang.   

Abstract

BACKGROUND: Bone marrow mesenchymal stem cells (MSC) mediate their protection by paracrine mechanism under ischemic conditions and anoxic pre-conditioning (AP) of MSC strongly enhances their survival and regenerative capacity. However, there is no report about the therapeutic potency of MSC transplantation on diabetic cardiomyopathy (DCM), an important cause of heart failure. METHODS AND
RESULTS: Four months after streptozotocin injection, diabetic rats were randomly given an intramyocardial injection of one of the following: DMEM, MSC, or AP-MSC (no.=10 for each group). Two weeks after transplantation, MSC, especially AP-MSC greatly increased the fractional shortening of diabetic heart (p<0.01, respectively). AP-MSC increased the capillary density of diabetic myocardium and attenuated myocardial fibrosis (p<0.01, respectively) by increasing the activity of matrix metalloproteinase-2 and inhibitiing transforming growth factor beta-1 (p<0.01, respectively). AP-MSC are anti-apoptotic in the rat DCM model, possibly mediated through cardiac upregulation of Bcl-2/Bax ratio (p<0.05) and inhibiting the expression and activation of caspase- 3 (p<0.01).
CONCLUSION: Intramyocardial transplantation of MSC has a protective effect on diabetic myocardium and anoxic pre-conditioning can enhance this protective effect. AP-MSC transplantation improved cardiac function in the rat DCM model, possibly through an anti-apoptotic effect on diabetic myocarium and attenuation of cardiac remodeling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362500     DOI: 10.1007/BF03345575

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  17 in total

1.  Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells.

Authors:  Massimiliano Gnecchi; Huamei He; Olin D Liang; Luis G Melo; Fulvio Morello; Hui Mu; Nicolas Noiseux; Lunan Zhang; Richard E Pratt; Joanne S Ingwall; Victor J Dzau
Journal:  Nat Med       Date:  2005-04       Impact factor: 53.440

2.  Efficacy of pancreatic transplantation on cardiovascular alterations in diabetic rats: an ultrastructural and immunohistochemical study.

Authors:  T Hayashi; M Nozawa; K Sohmiya; H Toko; M Nakao; M Okabe; F Terasaki; Y Kitaura; K Kawamura
Journal:  Transplant Proc       Date:  1998-03       Impact factor: 1.066

3.  The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model.

Authors:  Sang Yup Lim; Yong Sook Kim; Youngkeun Ahn; Myung Ho Jeong; Moon Hwa Hong; Soo Yeon Joo; Kwang Il Nam; Jeong Gwan Cho; Peter M Kang; Jong Chun Park
Journal:  Cardiovasc Res       Date:  2006-03-06       Impact factor: 10.787

4.  Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair.

Authors:  Shujia Jiang; Husnain Kh Haider; Niagara M Idris; Asmat Salim; Muhammad Ashraf
Journal:  Circ Res       Date:  2006-09-07       Impact factor: 17.367

Review 5.  Molecular and cellular mechanisms of myocardial failure.

Authors:  W S Colucci
Journal:  Am J Cardiol       Date:  1997-12-04       Impact factor: 2.778

6.  Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling.

Authors:  Ryota Uemura; Meifeng Xu; Nauman Ahmad; Muhammad Ashraf
Journal:  Circ Res       Date:  2006-05-11       Impact factor: 17.367

7.  Differentiation of bone marrow stromal cells into the cardiac phenotype requires intercellular communication with myocytes.

Authors:  Meifeng Xu; Maqsood Wani; Yan-Shan Dai; Jiang Wang; Mei Yan; Ahmar Ayub; Muhammad Ashraf
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

8.  Improved angiogenic potency by implantation of ex vivo hypoxia prestimulated bone marrow cells in rats.

Authors:  Tao-Sheng Li; Kimikazu Hamano; Kazuhiko Suzuki; Hiroshi Ito; Nobuya Zempo; Masunori Matsuzaki
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-08       Impact factor: 4.733

9.  Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1beta.

Authors:  Zhonglin Xie; Mahipal Singh; Krishna Singh
Journal:  J Biol Chem       Date:  2004-07-21       Impact factor: 5.157

Review 10.  Diabetic heart dysfunction: is cell transplantation a potential therapy?

Authors:  Joel Price; Subodh Verma; Ren-Ke Li
Journal:  Heart Fail Rev       Date:  2003-07       Impact factor: 4.214

View more
  51 in total

Review 1.  Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step.

Authors:  James D Richardson; Adam J Nelson; Andrew C W Zannettino; Stan Gronthos; Stephen G Worthley; Peter J Psaltis
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

2.  Use of human embryonic stem cell derived-mesenchymal cells for cardiac repair.

Authors:  David L Simpson; Nolan L Boyd; Sunjay Kaushal; Steve L Stice; Samuel C Dudley
Journal:  Biotechnol Bioeng       Date:  2011-09-02       Impact factor: 4.530

3.  The caspase-8 shRNA-modified mesenchymal stem cells improve the function of infarcted heart.

Authors:  Yeyou Liang; Qiuxiong Lin; Jiening Zhu; Xiaohong Li; Yongheng Fu; Xiao Zou; Xiaoying Liu; Honghong Tan; Chunyu Deng; Xiyong Yu; Zhixin Shan; Weiwei Yuan
Journal:  Mol Cell Biochem       Date:  2014-07-25       Impact factor: 3.396

4.  ES cells overexpressing microRNA-1 attenuate apoptosis in the injured myocardium.

Authors:  Carley Glass; Dinender K Singla
Journal:  Mol Cell Biochem       Date:  2011-06-14       Impact factor: 3.396

5.  Fibrin microbeads loaded with mesenchymal cells support their long-term survival while sealed at room temperature.

Authors:  Raphael Gorodetsky; Lilia Levdansky; Elena Gaberman; Olga Gurevitch; Esther Lubzens; William H McBride
Journal:  Tissue Eng Part C Methods       Date:  2011-05-25       Impact factor: 3.056

6.  Activated platelets interfere with recruitment of mesenchymal stem cells to apoptotic cardiac cells via high mobility group box 1/Toll-like receptor 4-mediated down-regulation of hepatocyte growth factor receptor MET.

Authors:  Sebastian Vogel; Madhumita Chatterjee; Katja Metzger; Oliver Borst; Tobias Geisler; Peter Seizer; Iris Müller; Andreas Mack; Susanne Schumann; Hans-Jörg Bühring; Florian Lang; Rüdiger V Sorg; Harald Langer; Meinrad Gawaz
Journal:  J Biol Chem       Date:  2014-02-24       Impact factor: 5.157

Review 7.  Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells.

Authors:  Andrey A Karpov; Daria V Udalova; Michael G Pliss; Michael M Galagudza
Journal:  Cell Prolif       Date:  2016-11-23       Impact factor: 6.831

8.  Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Can Preconditioning Strategies Improve Therapeutic Efficacy?

Authors:  Richard Schäfer; Gabriele Spohn; Patrick C Baer
Journal:  Transfus Med Hemother       Date:  2016-07-20       Impact factor: 3.747

Review 9.  The potential of cell-based therapy for diabetes and diabetes-related vascular complications.

Authors:  Aaron Liew; Timothy O'Brien
Journal:  Curr Diab Rep       Date:  2014-03       Impact factor: 4.810

10.  Aging-related decrease of human ASC angiogenic potential is reversed by hypoxia preconditioning through ROS production.

Authors:  Sandra De Barros; Stéphanie Dehez; Emmanuelle Arnaud; Corinne Barreau; Alexandre Cazavet; Guillaume Perez; Anne Galinier; Louis Casteilla; Valérie Planat-Bénard
Journal:  Mol Ther       Date:  2012-10-16       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.